3rd European Conference on Clinical research

conference clinical research


As you know, the third EUCROF Conference  took place in Prague.

Under the subtitle „Flying to 2020: Managing  Turbulences of  Innovation and Change“  EUCROF together with ACRO-CZ were hosting a meeting of more than 200 attendees from 25 countries at the Prague Congress Centre.

The Day 1 was started by a Press Morning  that was organized in a co-operation with the local Association of the Innovative Pharmaceutical Industry (AIFP).  The main topic of the Press Morning was telemedicine and related  devices used mainly, but not only in clinical trials – e.g. remote monitoring in cardiology.

The Key Note Speech after the opening of the scientific programme of the conference was  given by Michael Engsig  from PPD.  Michael presented the main feature of the current world of clinical research – the permanent change – as an opportunity for  positive development,  and as the only option to be successful in the never ending story of competition on the market.

The regulatory session included information on the  new EU Clinical Trials Portal and ICH-GCP Addendum.  It was interesting to hear that the Japanese delegation has not signed yet the revised ICG-GCP document (Step 4). This is expected to happen now, in November 2016. Implementation (Step 5), may be reached in mid 2017.  The Single EU Portal should ensure that  there is only one application dossier needed for each clinical trial or a modification to it, and a coordinated approach to clinical trial authorisation and supervision.  An uniform procedure is to be implemented in EU both for single or multi-country clinical trials. There is to be one reporting member state and a common assessment  by all concerned member states together. Clinical Trials Portal will also provide publicly available information. This system should go live in Oct 2018.

Internet of Things – and its strong impact on clincial research – this was the topic of one of the afternoon parallel sessions. Examples:  Devices to measure, devices to monitor health- like various wearable devices ( e.g.bracelets). Devices reminding the patients of their medications or procedures. Devices alerting the caregivers or physicians.  3D printers for medications.

The second parallell session  dealt with Post-Marketing Approaches: non-interventional studies, low intervention  studies, pharmacoepidemiology.

On Day 2 the most attractive session started right in the morning: Risk Based Monitoring.  Traditional approach with  100% onsite SDV every 4-6 weeks used to be perceived to be the FDA’s preferred method. However, now the modern approach prevails, with the focus on critical study data and processes, flexible visit frequence following risk analysis, and combination of onsite and remote monitoring. New technologies, and avoiding issues rather than correcting issues.  Despite the positive attitude of regulatory authorities we still also see reluctance  of  CRAs  to change the approach to monitoring. In the last 2 years this has not changed, and surprisingly also the experience of CRAs with risk based monitoring has not been so widespread as it could have been expected.

Parallel sessions on Day 2 were quite specific: Paediatric Clinical Trials, paediatric netwokrs for clinical research in particular,  and Medical Devices:  the Medical Devices Regulation, differences from clinical research with medications, implantable devices, in vitro diagnostics.

The last session of the conference was dedicated to Patient-centric Approach. This approach is not focusing just on the  clinical trial subject , but also e.g. on the role of so called „big data“ in healthcare. Healthcare systems produce an enormous amount of data that could be pooled, processed and used to be of a benefit  for  other patients – as a data bank of knowledge for physicians, as a tool to help diagnostic procedures, etc.  On the other hand, patient-centric approach also includes educating representatives of patients and patient organizations  to that they are able to be partners in clinical trial design and conduct.

The scientific programme of the conference was very busy, there was no time for sightseeing. However, we had fun during the Dancing Evening on Day 1.

The 3rd EUCROF Conference was a successful meeting, and so there already is no doubt that EUCROF is going  to continue the conference tradition. The ACRO-CZ organizational team was really pleased that the delegates liked Prague as the venue, and will now hand over to the next European city.

Darina Hrdlickova